Key result
A higher dose regimen of tirofiban achieved an inhibition of platelet aggregation of at least 80% in all test systems, whereas the lower dose regimen did not.
Why the study?
Does a higher dose regimen of tirofiban achieve better platelet inhibition compared to a standard dose regimen in patients undergoing percutaneous coronary intervention?
Does a higher dose regimen of tirofiban achieve better platelet inhibition compared to a standard dose regimen in patients undergoing percutaneous coronary intervention?
A higher dose regimen of tirofiban (15 microg/kg bolus, 0.15 microg/kg/min infusion) is required to consistently achieve at least 80% platelet inhibition across different assay methods and anticoagulants in PCI patients.
Higher-dose tirofiban may ensure target inhibition in PCI; hypothesis-generating for ischemic outcomes.
The primary objective of this study was to compare the inhibitory activity of tirofiban measured with the rapid platelet function assay (RPFA) and with light transmission aggregometry using two different anticoagulants (citrate versus PPACK). Twenty patients treated with tirofiban for percutaneous coronary intervention were studied at six time points during tirofiban treatment. Tirofiban was given with a bolus dose of 10 microg/kg and an infusion of 0.10 microg/kg per min (10 patients) or with a bolus dose of 15 microg/kg and an infusion of 0.15 microg/kg per min (10 patients). Inhibition of platelet function appeared highest using citrated blood and the RPFA-device and lowest when assessed by aggregometry in PPACK-anticoagulated blood. Only the higher dose of tirofiban achieved an inhibition of platelet aggregation of at least 80% in all test systems.
No takes yet. Share an insight, caveat, or question.
Voß et al. (2005) studied Percutaneous coronary intervention (n=20). Tirofiban higher dose regimen vs. Tirofiban lower dose regimen (10 microg/kg bolus and 0.10 microg/kg per min infusion) was evaluated on Inhibitory activity of tirofiban (platelet function inhibition). A higher dose regimen of tirofiban achieved an inhibition of platelet aggregation of at least 80% in all test systems, whereas the lower dose regimen did not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: